Therefore, while SREBP1 and ChREBP are critical amplifiers of hepatic steatosis, the underlying metabolic perturbation—diversion of glucose from glycogen synthesis—provides a fundamental drive for the increase in lipid accumulation. The gene discussed is MLXIPL; the disease is fatty liver disease.